{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T06:33:12Z","timestamp":1789021992953,"version":"build-2803163510"},"reference-count":65,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.numecd.2023.10.035","type":"journal-article","created":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:57:08Z","timestamp":1699365428000},"page":"537-547","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effect of omega-3 fatty acids supplementation on the prognosis of coronary artery disease: A meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7694-939X","authenticated-orcid":false,"given":"Tiantian","family":"Chao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaru","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5678-7592","authenticated-orcid":false,"given":"Chenglong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2023.10.035_bib1","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2023.10.035_bib2","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart disease and stroke statistics-2023 update: a report from the American heart association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2023.10.035_bib3","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2023.10.035_bib4","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/j.jacc.2020.03.033","article-title":"Low-density lipoprotein cholesterol: lower is totally better","volume":"75","author":"Cannon","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2023.10.035_bib5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/clinchem\/hvaa252","article-title":"Residual cardiovascular risk at low LDL: remnants, lipoprotein(a), and inflammation","volume":"67","author":"Hoogeveen","year":"2021","journal-title":"Clin Chem"},{"key":"10.1016\/j.numecd.2023.10.035_bib6","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s12967-022-03448-x","article-title":"Synergistic effect of the commonest residual risk factors, remnant cholesterol, lipoprotein(a), and inflammation, on prognosis of statin-treated patients with chronic coronary syndrome","volume":"20","author":"Liu","year":"2022","journal-title":"J Transl Med"},{"key":"10.1016\/j.numecd.2023.10.035_bib7","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2023.10.035_bib8","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1210\/er.2018-00184","article-title":"The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk","volume":"40","author":"Sandesara","year":"2019","journal-title":"Endocr Rev"},{"key":"10.1016\/j.numecd.2023.10.035_bib9","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jamacardio.2016.4828","article-title":"Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes","volume":"2","author":"Elam","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.numecd.2023.10.035_bib10","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2023.10.035_bib11","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.jacc.2022.02.035","article-title":"Prevention of cardiovascular events and mortality with icosapent ethyl in patients with prior myocardial infarction","volume":"79","author":"Gaba","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2023.10.035_bib12","doi-asserted-by":"crossref","first-page":"108172","DOI":"10.1016\/j.pharmthera.2022.108172","article-title":"Reducing residual cardiovascular risk in Europe: therapeutic implications of European medicines agency approval of icosapent ethyl\/eicosapentaenoic acid","volume":"237","author":"Chapman","year":"2022","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.numecd.2023.10.035_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21041362","article-title":"Marine omega-3 (N-3) fatty acids for cardiovascular health: an update for 2020","volume":"21","author":"Innes","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.numecd.2023.10.035_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/nu13093184","article-title":"Cardioprotective effects of nutraceuticals: focus on omega-3 polyunsaturated fatty acids","volume":"13","author":"Sypniewska","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.numecd.2023.10.035_bib15","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1161\/CIRCULATIONAHA.110.948562","article-title":"OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction","volume":"122","author":"Rauch","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2023.10.035_bib16","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1161\/CIRCULATIONAHA.120.052209","article-title":"Effects of n-3 fatty acid supplements in elderly patients after myocardial infarction: a randomized, controlled trial","volume":"143","author":"Kalstad","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2023.10.035_bib17","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013543","article-title":"Marine omega-3 supplementation and cardiovascular disease: an updated meta-analysis of 13 randomized controlled trials involving 127 477 participants","volume":"8","author":"Hu","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.numecd.2023.10.035_bib18","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.mayocp.2020.08.034","article-title":"Effect of omega-3 dosage on cardiovascular outcomes: an updated meta-analysis and meta-regression of interventional trials","volume":"96","author":"Bernasconi","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.numecd.2023.10.035_bib19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.mayocp.2016.10.018","article-title":"A meta-analysis of randomized controlled trials and prospective cohort studies of eicosapentaenoic and docosahexaenoic long-chain omega-3 fatty acids and coronary heart disease risk","volume":"92","author":"Alexander","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.numecd.2023.10.035_bib20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2023.10.035_bib21","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12872-019-1086-3","article-title":"Omega 3 fatty acid supplementation after myocardial infarction: a systematic review and meta-analysis","volume":"19","author":"Popoff","year":"2019","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.numecd.2023.10.035_bib22","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/07853890802698834","article-title":"Prevention of sudden cardiac death with omega-3 fatty acids in patients with coronary heart disease: a meta-analysis of randomized controlled trials","volume":"41","author":"Zhao","year":"2009","journal-title":"Ann Med"},{"key":"10.1016\/j.numecd.2023.10.035_bib23","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0002-9343(01)01114-7","article-title":"N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials","volume":"112","author":"Bucher","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.numecd.2023.10.035_bib24","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.numecd.2023.10.035_bib25","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/CIR.0000000000000156","volume":"132","author":"Hicks","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2023.10.035_bib26","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.numecd.2023.10.035_bib27","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.numecd.2023.10.035_bib28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12874-017-0315-7","article-title":"Trial Sequential Analysis in systematic reviews with meta-analysis","volume":"17","author":"Wetterslev","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.numecd.2023.10.035_bib29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11883-022-01079-7","article-title":"Highlights of cardiovascular disease prevention studies presented at the 2022 American heart association scientific sessions","volume":"25","author":"Gupta","year":"2023","journal-title":"Curr Atherosclerosis Rep"},{"key":"10.1016\/j.numecd.2023.10.035_bib30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0002-9149(97)89130-8","article-title":"Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency","volume":"77","author":"Eritsland","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.numecd.2023.10.035_bib31","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/ajcn\/74.1.50","article-title":"Effects of a high-dose concentrate of n-3 fatty acids or corn oil introduced early after an acute myocardial infarction on serum triacylglycerol and HDL cholesterol","volume":"74","author":"Nilsen","year":"2001","journal-title":"Am J Clin Nutr"},{"issue":"Suppl","key":"10.1016\/j.numecd.2023.10.035_bib32","first-page":"S99","article-title":"The effect of n-3 fatty acids on coronary atherosclerosis: results from SCIMO, an angiographic study, background and implications","volume":"36","author":"von Schacky","year":"2001","journal-title":"Lipids"},{"key":"10.1016\/j.numecd.2023.10.035_bib33","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(99)07072-5","article-title":"Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial","volume":"354","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2023.10.035_bib34","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.numecd.2023.10.035_bib35","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0140-6736(08)61239-8","article-title":"Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.numecd.2023.10.035_bib36","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMoa1003603","article-title":"n-3 fatty acids and cardiovascular events after myocardial infarction","volume":"363","author":"Kromhout","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2023.10.035_bib37","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ijcard.2016.11.105","article-title":"Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes of a randomized controlled study","volume":"228","author":"Nosaka","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.numecd.2023.10.035_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2022.11.008","volume":"257","author":"Nishizaki","year":"2023","journal-title":"Am Heart J"},{"key":"10.1016\/j.numecd.2023.10.035_bib39","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1161\/CIRCULATIONAHA.122.059410","volume":"146","author":"Ridker","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2023.10.035_bib40","doi-asserted-by":"crossref","first-page":"e867","DOI":"10.1161\/CIR.0000000000000482","article-title":"Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American heart association","volume":"135","author":"Siscovick","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2023.10.035_bib41","series-title":"EMA confirms omega-3 fatty acid medicines are not effective in preventing further heart problems after a heart attack","year":"2019"},{"key":"10.1016\/j.numecd.2023.10.035_bib42","series-title":"FDA approves use of drug to reduce risk of cardiovascular events in certain adult patient groups","author":"Us Food and Drug Administration","year":"2019"},{"key":"10.1016\/j.numecd.2023.10.035_bib43","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jacl.2019.10.014","article-title":"National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk","volume":"13","author":"Orringer","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.numecd.2023.10.035_bib44","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2023.10.035_bib45","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2023.10.035_bib46","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.2337\/dc22-S010","article-title":"Cardiovascular disease and risk management: standards of medical care in diabetes\u20142022","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2023.10.035_bib47","doi-asserted-by":"crossref","first-page":"105060","DOI":"10.1016\/j.phrs.2020.105060","article-title":"Omega-3 polyunsaturated fatty acids supplementation and cardiovascular outcomes: do formulation, dosage, and baseline cardiovascular risk matter? An updated meta-analysis of randomized controlled trials","volume":"160","author":"Casula","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.numecd.2023.10.035_bib48","doi-asserted-by":"crossref","first-page":"809311","DOI":"10.3389\/fnut.2022.809311","article-title":"Omega-3 fatty acid supplementation and coronary heart disease risks: a meta-analysis of randomized controlled clinical trials","volume":"9","author":"Shen","year":"2022","journal-title":"Front Nutr"},{"key":"10.1016\/j.numecd.2023.10.035_bib49","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/jamacardio.2017.5205","article-title":"Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals","volume":"3","author":"Aung","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.numecd.2023.10.035_bib50","first-page":"1536","article-title":"Omega-3 fatty acids, cardiovascular risk, and the resolution of inflammation","volume":"33","author":"B\u00e4ck","year":"2019","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol"},{"key":"10.1016\/j.numecd.2023.10.035_bib51","doi-asserted-by":"crossref","first-page":"104462","DOI":"10.1016\/j.phrs.2019.104462","article-title":"Omega-3 fatty acids supplementation and oxidative stress parameters: a systematic review and meta-analysis of clinical trials","volume":"149","author":"Heshmati","year":"2019","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.numecd.2023.10.035_bib52","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0735-1097(99)00548-3","article-title":"Dietary supplementation with marine omega-3 fatty acids improve systemic large artery endothelial function in subjects with hypercholesterolemia","volume":"35","author":"Goodfellow","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2023.10.035_bib53","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.vph.2013.08.002","article-title":"Antiplatelet properties of natural products","volume":"59","author":"Vilahur","year":"2013","journal-title":"Vasc Pharmacol"},{"key":"10.1016\/j.numecd.2023.10.035_bib54","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.atherosclerosis.2010.05.022","article-title":"Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased\u00a0plaque inflammation and increased stability","volume":"212","author":"Cawood","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2023.10.035_bib55","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jacc.2020.11.060","article-title":"Cardiovascular impact of nutritional supplementation with omega-3 fatty acids: JACC focus seminar","volume":"77","author":"Weinberg","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2023.10.035_bib56","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S1734-1140(13)70964-2","article-title":"Effects of n-3 polyunsaturated fatty acids on depressive symptoms, anxiety and emotional state in patients with acute myocardial infarction","volume":"65","author":"Haberka","year":"2013","journal-title":"Pharmacol Rep PR"},{"key":"10.1016\/j.numecd.2023.10.035_bib57","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/j.jacc.2011.06.063","article-title":"Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events","volume":"58","author":"Mozaffarian","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2023.10.035_bib58","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1042\/BST20160474","article-title":"Omega-3 fatty acids and inflammatory processes: from molecules to man","volume":"45","author":"Calder","year":"2017","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.numecd.2023.10.035_bib59","series-title":"Omega-3 fat. Acids keys nutr. Health","first-page":"67","article-title":"Omega-3 polyunsaturated fatty acids and hyperlipidaemias","author":"Ferguson","year":"2016"},{"key":"10.1016\/j.numecd.2023.10.035_bib60","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1016\/j.bbamem.2016.10.002","article-title":"Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes","volume":"1858","author":"Mason","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.numecd.2023.10.035_bib61","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12944-016-0286-4","article-title":"The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia","volume":"15","author":"Backes","year":"2016","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.numecd.2023.10.035_bib62","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1016\/j.jacc.2020.09.005","article-title":"A revolution in omega-3 fatty acid research","volume":"76","author":"Bhatt","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2023.10.035_bib63","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.plipres.2014.09.001","article-title":"Omega-3 long chain fatty acid \u201cbioavailability\u201d: a review of evidence and methodological considerations","volume":"56","author":"Ghasemifard","year":"2014","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.numecd.2023.10.035_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.plefa.2013.03.010","article-title":"Bioavailability of long-chain omega-3 fatty acids","volume":"89","author":"Schuchardt","year":"2013","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.numecd.2023.10.035_bib65","doi-asserted-by":"crossref","first-page":"515","DOI":"10.7326\/0003-4819-158-7-201304020-00003","article-title":"Plasma phospholipid long-chain \u03c9-3 fatty acids and total and cause-specific mortality in older adults: a cohort study","volume":"158","author":"Mozaffarian","year":"2013","journal-title":"Ann Intern Med"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475323004428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475323004428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:27:17Z","timestamp":1760545637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475323004428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0939475323004428"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2023.10.035","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of omega-3 fatty acids supplementation on the prognosis of coronary artery disease: A meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2023.10.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}